Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

L. G. Estévez; E. García; M. Hidalgo

doi:10.1007/s12094-015-1410-z

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

L. G. Estévez, E. García, M. Hidalgo

School of Medicine

Research output: Contribution to journal › Review article › peer-review

6 Scopus citations

Abstract

Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.

Original language	English (US)
Pages (from-to)	541-549
Number of pages	9
Journal	Clinical and Translational Oncology
Volume	18
Issue number	6
DOIs	https://doi.org/10.1007/s12094-015-1410-z
State	Published - Jun 1 2016

Keywords

Breast cancer
Buparlisib
PI3K inhibitor
PI3KCA
Targeted therapy

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.1007/s12094-015-1410-z

Cite this

@article{cd7cfb54a8bd4150b3eae86752f7a30e,

title = "Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma",

abstract = "Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.",

keywords = "Breast cancer, Buparlisib, PI3K inhibitor, PI3KCA, Targeted therapy",

author = "Est{\'e}vez, {L. G.} and E. Garc{\'i}a and M. Hidalgo",

note = "Publisher Copyright: {\textcopyright} 2015, Federaci{\'o}n de Sociedades Espa{\~n}olas de Oncolog{\'i}a (FESEO).",

year = "2016",

month = jun,

day = "1",

doi = "10.1007/s12094-015-1410-z",

language = "English (US)",

volume = "18",

pages = "541--549",

journal = "Clinical and Translational Oncology",

issn = "1699-048X",

publisher = "Springer-Verlag Italia",

number = "6",

}

TY - JOUR

T1 - Inhibiting the PI3K signaling pathway

T2 - buparlisib as a new targeted option in breast carcinoma

AU - Estévez, L. G.

AU - García, E.

AU - Hidalgo, M.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.

AB - Aberrations in the PI3K signaling pathway are frequently observed in patients with breast cancer. Because of that, PI3K inhibitors are attractive options for the treatment of breast cancer because PI3K is the most proximal component of the pathway other than receptor tyrosine kinases. Buparlisib is a potent and highly specific oral pan-class I PI3K inhibitor, which is currently under investigation in patients with breast cancer. In this article, we describe the PI3K signaling pathway, the prognostic value of PI3K pathway mutations, as well as the mechanism of action of buparlisib. Lastly, we discuss preliminary results of preclinical and clinical studies showing the efficacy and safety profile of this agent in breast cancer patients.

KW - Breast cancer

KW - Buparlisib

KW - PI3K inhibitor

KW - PI3KCA

KW - Targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84945531466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84945531466&partnerID=8YFLogxK

U2 - 10.1007/s12094-015-1410-z

DO - 10.1007/s12094-015-1410-z

M3 - Review article

C2 - 26510854

AN - SCOPUS:84945531466

SN - 1699-048X

VL - 18

SP - 541

EP - 549

JO - Clinical and Translational Oncology

JF - Clinical and Translational Oncology

IS - 6

ER -

Inhibiting the PI3K signaling pathway: buparlisib as a new targeted option in breast carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this